600993.SH上海证券交易所 · 主板 Main
Mayinglong Pharmaceutical Group 马应龙
Traditional Chinese Medicine 中药Ⅱ
¥22.27+¥0.12 · +0.54%
Open 开盘
¥22.15
High 最高
¥22.32
Low 最低
¥22.12
Prev Close 昨收
¥22.15
Volume 成交量
160.9万股
Turnover 成交额
¥3,576.2万
Mkt Cap 总市值
¥96亿
P/E 市盈率
16.0×
Recent Activity 近期动态All Filings 全部公告 →
2 significant filings since 31 May 2026: 1 on dividend and 1 on management change. The latest, on 26 Aug 2026: 马应龙关于公司总经理离任及聘任总经理的公告.
自 31 May 2026 起有 2 份重大公告：dividend 1 份、management change 1 份。最新一份（26 Aug 2026）：马应龙关于公司总经理离任及聘任总经理的公告。
Price History 价格走势
1 session 个交易日, Mon 28 Sep 2026 · Live one-minute prices · High 最高 ¥22.31 · Low 最低 ¥22.14 · +0.63% on the previous close of ¥22.1522.15022.17522.20022.22522.25022.27522.300
Volume 成交量
641
09:3010:0610:4211:1813:23
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Traditional Chinese Medicine 中药Ⅱ · 66 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥96亿 | ¥60亿 | 19th highest of 66 · 66 家中第 19 高 | |
| Trailing P/E 市盈率 | 16.0x | 31.6x | 10th lowest of 49 · 49 家中第 10 低 | |
| P/B 市净率 | 2.2x | 2.2x | 33rd lowest of 65 · 65 家中第 33 低 | |
| Revenue Growth 营收增速 | 3.2% | -7.4% | 12th highest of 66 · 66 家中第 12 高 | |
| Profit Growth 净利增速 | 5.6% | -0.2% | 25th highest of 66 · 66 家中第 25 高 | |
| Gross Margin 毛利率 | 46.9% | 56.9% | 20th lowest of 66 · 66 家中第 20 低 | |
| Net Margin 净利率 | 18.7% | 9.6% | 18th highest of 66 · 66 家中第 18 高 | |
| Return on Equity 净资产收益率 | 8.0% | 3.0% | 10th highest of 65 · 65 家中第 10 高 | |
| Debt to Assets 资产负债率 | 20.6% | 28.4% | 20th lowest of 66 · 66 家中第 20 低 | |
| Grade Score 评级得分 | 69 | 52 | 8th highest of 66 · 66 家中第 8 高 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥899亿 | 17.2x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥705亿 | 39.0x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥390亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥315亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥290亿 | 16.2x | 2.9x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥270亿 | 31.8x | 4.5x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥226亿 | 12.3x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Tasly 天士力 | ¥205亿 | 16.8x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥205亿 | 6.5x | 0.6x | -8.5% | 198.7% | 6.5% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥195亿 | 97.6x | 4.9x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥184亿 | 624.3x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥152亿 | 64.4x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Mayinglong Pharmaceutical Group 马应龙 | ¥96亿 | 16.0x | 2.2x | 3.2% | 18.7% | 8.0% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。